Calendar Year 1990

Initial Public Offering

Calendar Year 1991

Initial Launch of Pharmaceutical Products

Established Dermatological Sales Force

Acquired ESOTERICA® from SmithKline Beecham

Calendar Year 1992

Calendar Year 1993

Introduced DYNACIN®

Calendar Year 1994

No Data Available

Calendar Year 1995

Relocated to Phoenix, AZ

Launched TRIAZ®

Calendar Year 1996

1 for 14 Reverse Stock Split

Introduced Dye-Free DYNACIN®

3 for 2 Stock Split

Calendar Year 1997

3 for 2 Stock Split

Completed Public Offering Raising More Than $95 Million

Acquired LIDEX® and SYNALAR® from Syntex

Collaboration with Abbott Laboratories

Received Patent for TRIAZ®

Acquired GenDerm Corporation

Calendar Year 1998

Completed Public Offering Raising More Than $210 Million

Launched LUSTRA®

Listed on NYSE

Acquired LOPROX® and TOPICORT® from Aventis (HMR)

Calendar Year 1999

Began Promotion to Podiatrists

3 for 2 Stock Split

Sold and Licensed Products to Bioglan

Acquired Ucyclyd Pharma Inc.

Launched LUSTRA-AF®

Launched DYNACIN® 75 mg

Received Patent on LUSTRA® Composition

Acquired VECTRIN Product Line from Warner Chilcott

Chairman and CEO Selected to Serve on NYSE Advisory Committee

Launched LOPROX® Gel

Calendar Year 2000

Established Stock Repurchase Program

Launched OVIDE®

Relocated to Scottsdale, AZ

Calendar Year 2001

Launched PLEXION® and PLEXION® TS

Collaboration with Corixa

Announced PVAC™ Phase II Trial Preliminary Results

Licensed OMNICEF® from Abbott Laboratories for Dermatology and Podiatry in U.S.

Launched ALUSTRA®

Completed Merger with Ascent Pediatrics

Began Promotion to Pediatricians

Calendar Year 2002

Launched PLEXION SCT®

Issued $350 Million Contingent Convertible Senior Notes Due 2032

Strategic Alliance with aaiPharma

License and Development Agreement with Dow Pharmaceutical Sciences

Calendar Year 2003

Launched LOPROX® TS

Licensed Four Branded Products to Taro

Acquired Exclusive License to RESTYLANE® Family of Products

Launched LOPROX® Shampoo

Launched DYNACIN® Tablets

Declared First Dividend

Launched TRIAZ® Pads

Completed Exchange Offer for Contingent Convertible Senior Notes Due 2033

Discontinued PVAC™ Development

Calendar Year 2004

2 for 1 Stock Split

Launched RESTYLANE®

Licensed ORAPRED® to BioMarin

Licensed RESTYLANE^® and SubQ from Q-Med AB

Licensed LUSTRA® Family of Products to Taro

Launched PLEXION® Cleansing Cloths

Licensed Proprietary Peptide Technology from Ansata Therapeutics

Calendar Year 2005

Supermodel Frederique van der Wal Signed on as the New Face of RESTYLANE^®

FDA Approved NDA for VANOS^™

FDA Approved AMMONUL^®

Launched Restylane Rewards^℠

Announced Agreement to Merge with Inamed

Filed Suit Against Upsher-Smith and Prasco

Board Unanimously Rejected Mentor Proposal

Requested That Inamed Recommend Rejection of Allergan Exchange Offer

Terminated Merger Agreement with Inamed; Received $90 Million Termination Fee

Calendar Year 2006

FDA Approved Broader Indication for VANOS^®

Ipsen Granted Medicis Rights to Distribute and Promote RELOXIN^® for aesthetic use in the U.S.

Two Patents Issued for LOPROX^® Gel

FDA Approved SOLODYN^® -- minocycline HCl, USP -- Extended Release Tablets

Launched Search for the "Hottest Mom in America^™"

Medicis and Dow Pharmaceutical Sciences announce FDA Approval of ZIANA^® (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel

Calendar Year 2007

Launched ZIANA^®

Launched PERLANE^®

Launched TV Ad Campaign for RESTYLANE^®

Announced Strategic Collaboration with Hyperion Therapeutics

Announced Share Repurchase Program up to $200 Million

BLA for RELOXIN^® in Aesthetics Submitted to FDA

Announced Strategic Collaboration with Revance Therapeutics

Calendar Year 2008

Increased Cash Dividend to $0.04 Per Share

BLA for RELOXIN^® in Aesthetics Submitted to FDA by Ipsen

Announced Organizational Changes

BLA for RELOXIN^® in Aesthetics Accepted by FDA

Completed Acquisition of LipoSonix, Inc.

FDA Approved PMA Supplement for RESTYLANE^®

Announced R&D Collaboration and Settlement with Impax

Calendar Year 2009

Announced Notice of Allowance for SOLODYN^® 90mg

Announced New Notice of Allowance for SOLODYN^® 90mg

FDA Approved DYSPORT™ (abobotulinumtoxinA) for Therapeutic and Aesthetic Uses

Announced New Patents for SOLODYN^® 90mg

Launched DYSPORT™

Announced Approval of New Strengths of SOLODYN^®

Announced Notice of Allowance for SOLODYN^® Patent